Today, in Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012), the Federal Circuit held that non-naturally occurring DNA is patent eligible as well as the use of a transformed, non-naturally occurring cell for screening drug candidates. Myriad’s method claims directed to “comparing” or “analyzing” DNA sequences were held to be patent-ineligible. A copy of the Federal Circuit’s decision is attached Federal Circuit Myriad Decision. A detailed analysis by Foley & Lardner, LLP and this blog post will follow.
Related Insights
June 18, 2025
Foley Viewpoints
Legal Reasoning Still a Struggle for LLMs
The authors in this paper created a benchmark including long-form, open-ended questions and multiple-choice questions to evaluate the…
June 18, 2025
Health Care Law Today
HIPAA Risk Analyses for Digital Health: Navigating AI, M&A and Vendor Diligence
HIPAA Security Risk Analyses (SRAs) should be the foundation of every digital health company’s cybersecurity compliance. Far more than a…
June 17, 2025
Health Care Law Today
Oregon’s New Corporate Practice of Medicine Restrictions: Five Takeaways for Digital Health and Telemedicine Companies
On June 9, 2025, Oregon’s governor signed SB 951 into law, making Oregon one of the most restrictive states in the country with respect…